COVID19-ITS-KISS - Surveillance of infections and multidrug-resistant bacteria among COVID-19 patients in ICUs

• Conditions: U07.1; COVID-19, virus identified

• Registration Number: DRKS00025452
• Lead Sponsor: Projektträger JülichGründungs-, Technologietransfer- und InnovationsförderungInternationales Forschungszentrum Jülich GmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-05-28
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 5000

Inclusion Criteria

Patients diagnosed with COVID-19 (on admission or during their ICU stay)

Exclusion Criteria

Patients without COVID-19 and patients without admission to the participating IC

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
-Incidence and incidence densitiy (per 1000 patient days or per 1000 device-days) of ICU-acquired change of microorganism in existing respiratory infections<br>-Incidence and incidence density of new ICU-acquired respiratory infections<br>-Incidence and incidence density of new ICU-acquired blood stream infections<br>-Incidence and incidence densities of new ICU-acquired multidrug-resistant organisms (Methicillin-resistant Staphylococcus aureus, Vancomycin-resistant Enterococci, multidrug-resistant Gram-negative bacteria)

Secondary Outcome Measures

Name	Time	Method
-Admission prevalence of respiratory tract infections<br>-Rates of device use (invasive ventilation, non-invasive ventilation, central venous catheter, extracorporal membranous oxygenation)<br>-Incidence of secondary blood stream infections in patients with respiratory infections